Investigational drug · Phase 3
Povorcitinib
Also called: INCB054707, INCB54707
Not approved by FDA. In 12 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
12
9 still active
All registered trials
25
Any phase or sponsor naming "Povorcitinib"
First trial start
2022
Dec 19, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Povorcitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hidradenitis Suppurativa (HS)
- NonSegmental Vitiligo
- Prurigo Nodularis
- Moderate to Severe Asthma
- Urticaria
- Chronic Spontaneous Urticaria
- Chronic Idiopathic Urticaria
- Hives
- Angioedema
- Pruritis
Approved drugs for the same conditions: Hidradenitis suppurativa · Chronic hives (urticaria) · Asthma · Immunology and inflammation · Infectious disease and vaccines · Respiratory · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Povorcitinib" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT05620836 · 619 participants · Start Feb 22, 2023 · Primary completion Jan 7, 2025
Drug: Povorcitinib; Placebo · For: Hidradenitis Suppurativa (HS)
Sites: Scottsdale, Arizona; Arkansas City, Arkansas; Fayetteville, Arkansas · 101 sites in all
- A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT06212999 · 617 participants · Start Jan 30, 2024 · Primary completion Dec 26, 2026
Drug: Povorcitinib · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fort Smith, Arkansas · 165 sites in all
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT05620823 · 608 participants · Start Dec 19, 2022 · Primary completion Feb 3, 2025
Drug: Povorcitinib; Placebo · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Arkansas City, Arkansas; Fort Smith, Arkansas · 104 sites in all
- Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT06855498 · 600 participants (planned) · Start Feb 28, 2025 · Primary completion Feb 28, 2028
Drug: povorcitinib · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Montgomery, Alabama; Phoenix, Arizona · 305 sites in all
- A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)Pivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT06113445 · 467 participants · Start Nov 29, 2023 · Primary completion Feb 24, 2026
Drug: Povorcitinib; Placebo · For: NonSegmental Vitiligo
Sites: Hoover, Alabama; Irvine, California; Santa Monica, California · 100 sites in all
- A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)Pivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT06113471 · 450 participants · Start Nov 27, 2023 · Primary completion Mar 17, 2026
Drug: Povorcitinib; Placebo · For: NonSegmental Vitiligo
Sites: Birmingham, Alabama; Montgomery, Alabama; Fountain Valley, California · 86 sites in all
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)Pivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT06516952 · 349 participants · Start Oct 10, 2024 · Primary completion Oct 19, 2026
Drug: Povorcitinib; Placebo · For: Prurigo Nodularis
Sites: Birmingham, Alabama; Tucson, Arizona; Fayetteville, Arkansas · 120 sites in all
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)Pivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT06516965 · 346 participants · Start Oct 10, 2024 · Primary completion Sep 28, 2026
Drug: Povorcitinib; Placebo · For: Prurigo Nodularis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fountain Valley, California · 119 sites in all
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaPivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT05851443 · 247 participants · Start Jul 11, 2023 · Primary completion Nov 20, 2026
Drug: povorcitinib; ICS-LABA · For: Moderate to Severe Asthma
Sites: Birmingham, Alabama; Bakersfield, California; Upland, California · 82 sites in all
- To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis SuppurativaPivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT04476043 · 209 participants · Start Aug 25, 2020 · Primary completion Dec 15, 2021
Drug: INCB054707; Placebo · For: Hidradenitis Suppurativa; Acne Inversa
Sites: Hoover, Alabama; Gilbert, Arizona; Phoenix, Arizona · 40 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and Safety of JAK and TYK2 Inhibitors in Chronic Spontaneous Urticaria: A Systematic Review of 254 Patients.
Pourgholi E, Heidari S, Esmaeili F, et al. · J Cutan Med Surg 2026
- Onset, Depth, and 54-Week Follow-Up of Povorcitinib in Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review.
Alphonse C, Chiriyankandath Ignatius F · Cureus 2026
- Integrative transcriptomic and regulatory network analysis of molecular dysregulation and mechanistic complementarity in prurigo nodularis.
Tang J, Lin W, Lin Q, et al. · Comput Biol Chem 2026
- Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials.
Ezzedine K, Lui H, Eleftheriadou V, et al. · Nat Med 2026
- Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.
Porter ML, Martorell A, Sayed CJ, et al. · Nat Med 2026
- Comparative Pharmacologic Characterization of Povorcitinib (INCB054707) as a Highly Selective Oral JAK1 Inhibitor.
Wass B, Fenix AM, Zolotarjova N, et al. · Dermatol Ther (Heidelb) 2026
Also in development for Hidradenitis Suppurativa (HS)
- BFB759Phase 32 trials
Bluefin Biomedicine, Inc. · Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)
- LT-002-158Phase 23 trials
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)
- ORKA-002Phase 23 trials
Oruka Therapeutics, Inc. · Plaque Psoriasis, Hidradenitis Suppurativa (HS)
- CIT-013Phase 22 trials
Citryll BV · Hidradenitis Suppurativa (HS), Rheumatoid Arthritis
- CIT-013 dosePhase 22 trials
Citryll BV · Hidradenitis Suppurativa (HS), Rheumatoid Arthritis
- SL-325Phase 22 trials
Shattuck Labs, Inc. · Crohn's Disease, Hidradenitis Suppurativa (HS)
- SPY002-072SPY072Phase 22 trials
Spyre Therapeutics, Inc. · Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis
- TibulizumabZB-106Phase 22 trials
Zura Bio Inc · Hidradenitis Suppurativa (HS), Systemic Sclerosis (SSc), Scleroderma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Incyte.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.